Results 161 to 170 of about 10,873 (203)

Eplerenone: A Selective Aldosterone Blocker

Cardiovascular Drug Reviews, 2003
ABSTRACTRecent studies suggest that aldosterone may play a larger role than once appreciated in normal physiologic function and cardiovascular disease. Some of the adverse cardiovascular effects that have been described include cardiac and vascular fibrosis, vascular necrosis and inflammation, impaired endothelial function, reduced fibrinolysis ...
openaire   +2 more sources

Eplerenone

Practical Diabetes International, 2008
G Marshall, G McKay, M Fisher
openaire   +1 more source

Eplerenone for Chronic Central Serous Chorioretinopathy

Lancet, The, 2020
Giuseppe Querques, Enrico Borrelli, Riccardo Sacconi   +2 more
exaly   +2 more sources

Eplerenone

Reactions Weekly, 2023
openaire   +1 more source

Eplerenone

Drugs of the Future, 1999
X. Rabasseda, J. Silvestre, J. Castañer
openaire   +1 more source

Eplerenone (GD Searle & Co).

Current opinion in investigational drugs (London, England : 2000), 2001
Eplerenone, an aldosterone receptor antagonist from Searle is being developed as a potential treatment for renal disease, congestive heart failure and hypertension. It is in phase III clinical trials 1312280], [353548]. Monsanto (now Pharmacia) expects to launch the compound in 2002 [370466]. Pharmacia anticipates filing for congestive heart failure in
Martin, J. H., Krum, H.
openaire   +2 more sources

Eplerenone

Reactions Weekly, 2016
openaire   +2 more sources

Eplerenone for Chronic Central Serous Chorioretinopathy in Patients With Active, Previously Untreated Disease for More Than 4 Months (VICI): A Randomised, Double-Blind, Placebo-Controlled Trial

Lancet, The, 2020
Andrew J Lotery, Tunde Peto, Geeta Menon
exaly  

Eplerenone

Reactions Weekly, 2019
openaire   +1 more source

Eplerenone

2007
openaire   +1 more source